[HTML][HTML] Tumor microenvironment differences between primary tumor and brain metastases
B Cacho-Díaz, DR García-Botello… - Journal of Translational …, 2020 - Springer
The present review aimed to discuss contemporary scientific literature involving differences
between the tumor microenvironment (TME) in melanoma, lung cancer, and breast cancer in …
between the tumor microenvironment (TME) in melanoma, lung cancer, and breast cancer in …
[HTML][HTML] Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: a clash of the generations
R Shah, JF Lester - Clinical lung cancer, 2020 - Elsevier
The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
[HTML][HTML] Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis
S Edavettal, P Cejudo-Martin, B Dasgupta, D Yang… - Med, 2022 - cell.com
Background The near impermeability of the blood-brain barrier (BBB) and the unique
neuroimmune environment of the CNS prevents the effective use of antibodies in …
neuroimmune environment of the CNS prevents the effective use of antibodies in …
Gefitinib plus chemotherapy vs gefitinib alone in untreated EGFR-Mutant non–small cell lung Cancer in patients with brain metastases: the GAP BRAIN open-label …
X Hou, M Li, G Wu, W Feng, J Su, H Jiang… - JAMA network …, 2023 - jamanetwork.com
Importance Use of tyrosine kinase inhibitors (TKIs) is the standard therapy for epidermal
growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) with brain …
growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) with brain …
[HTML][HTML] Cancer driver gene and non-coding RNA alterations as biomarkers of brain metastasis in lung cancer: a review of the literature
Brain metastasis (BM) is the most common event in patients with lung cancer. Despite
multimodal treatments and advances in systemic therapies, development of BM remains one …
multimodal treatments and advances in systemic therapies, development of BM remains one …
[HTML][HTML] Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer
L Li, S Luo, H Lin, H Yang, H Chen, Z Liao… - Journal of thoracic …, 2017 - ncbi.nlm.nih.gov
Background Lung cancer is the leading cause of cancer-related death worldwide. Numerous
studies have been performed to investigate the correlation between epidermal growth factor …
studies have been performed to investigate the correlation between epidermal growth factor …
[HTML][HTML] Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma
C Deng, Y Zhang, Z Ma, F Fu, L Deng, Y Li… - The Journal of thoracic …, 2021 - Elsevier
Background Mutation of the EGFR gene is known as a predictor for the response to EGFR
tyrosine kinase inhibitor. Although EGFR mutation status is proposed to be incorporated in …
tyrosine kinase inhibitor. Although EGFR mutation status is proposed to be incorporated in …
[HTML][HTML] The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta …
WY Li, TT Zhao, HM Xu, ZN Wang, YY Xu, Y Han… - BMC cancer, 2019 - Springer
Background The brain is a common site for metastasis in non-small-cell lung cancer
(NSCLC). This study was designed to evaluate the relationship between the mutational of …
(NSCLC). This study was designed to evaluate the relationship between the mutational of …
[HTML][HTML] Hype or hope–Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant …
F Papini, J Sundaresan, A Leonetti, M Tiseo… - Critical Reviews in …, 2021 - Elsevier
Three generations of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-
TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer …
TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer …
[HTML][HTML] Genomic comparison between cerebrospinal fluid and primary tumor revealed the genetic events associated with brain metastasis in lung adenocarcinoma
Z Deng, L Cui, P Li, N Ren, Z Zhong, Z Tang… - Cell Death & …, 2021 - nature.com
Lung adenocarcinoma (LUAD) is most common pathological type of lung cancer. LUAD with
brain metastases (BMs) usually have poor prognosis. To identify the potential genetic factors …
brain metastases (BMs) usually have poor prognosis. To identify the potential genetic factors …